Tyrosine kinases are important in the signal transduction of a number of growth factors. As shown previously, transforming growth factor (TGF)-a stimulated proliferation of type I1 cells in vitro. The mitogenic effect of TGF-a could be blocked by the addition of the tyrosine kinase inhibitors genistein or tyrphostin. Tyrosine phosphorylation in type I1 cells exposed to growth factors was examined using an antiphosphotyrosine antibody. After addition of TGF-a, phosphorylation of a tyrosine protein with a molecular mass of 170 kD, presumed to be the epidermal growth factor receptor (EGF-R), peaked by 5 min, returning to baseline by 30 min. As expected, genistein or tyrphostin decreased the TGF-a-induced phosphorylation of the EGF-R. Addition of TGF-p resulted in no newly phosphorylated tyrosine proteins. TGF-P decreased the TGFa-induced phosphorylation of the EGF-R. Previous work has shown that TGF-P blocks the TGF-a stimulation of type I1 cell proliferation. It appears that TGF-p interferes with TGF-a-induced phosphorylation of the EGF-R.
Tyrosine kinases are important in the signal transduction of a number of growth factors. As shown previously, transforming growth factor (TGF)-a stimulated proliferation of type I1 cells in vitro. The mitogenic effect of TGF-a could be blocked by the addition of the tyrosine kinase inhibitors genistein or tyrphostin. Tyrosine phosphorylation in type I1 cells exposed to growth factors was examined using an antiphosphotyrosine antibody. After addition of TGF-a, phosphorylation of a tyrosine protein with a molecular mass of 170 kD, presumed to be the epidermal growth factor receptor (EGF-R), peaked by 5 min, returning to baseline by 30 min. As expected, genistein or tyrphostin decreased the TGF-a-induced phosphorylation of the EGF-R. Addition of TGF-p resulted in no newly phosphorylated tyrosine proteins. TGF-P decreased the TGFa-induced phosphorylation of the EGF-R. Previous work has shown that TGF-P blocks the TGF-a stimulation of type I1 cell proliferation. It appears that TGF-p interferes with TGF-a-induced phosphorylation of the EGF-R.
(Pediatr Res 36: 481-486, 1994)
Abbreviations TGF, transforming growth factor EGF, epidermal growth factor EGF-R, epidermal growth factor-receptor TBS, Tris-buffered saline 'H-TdFt, tritiated thymidine PDGF, platelet-derived growth factor Growth factors are important mediators of cellular func-is the first step initiating a complex cytosolic signal transtions in many systems, including normal pulmonary devel-duction cascade that ultimately results in gene transcripopment (1) (2) (3) . In addition, they are thought to play a role in tion in the nucleus (17) (18) (19) . the lung's response to cell injury (4). Type 11 alveolar TGF-p inhibits basal proliferation of type I1 pneumoepithelial cells are also important in lung injury, b~a u s e cytes, as well as the enhanced proliferation of type I1 they proliferate and differentiate into ~u l m o n a~ type I pneumocytes, in response to EGF or TGF-a (20) . TGF-p cells during the Process of epithelial regeneration (5, 6)-signal transduction is not well understood, although its The mechanism of this transfoxmation is not well under-type 11 receptor is believed to be a serine/threonine stood, but it is most likely regulated by growth factors.
kinase (21) . The specific mechanism involved in TGl7-p Growth factors that are in pulmonary type I1 antagonism of the proliferative effect of EGF and TGFa epithelial cell proliferation and differentiation include is also unknown, although activation of a serine/ EGF, TGF-a, and TGF-p. EGF has been shown to ac-threonine phosphatase in a step beyond activation of the celerate fetal lung maturation in viva (7-9)-EGF and TGF-P receptor has been implicated in other Systems (22, TGF-a have 40% and have similar 23). The present work examines the signal transduction effects (10, 11) . Both EGF and TGF-a exert their effects events that occur in type I1 cells after addition of TGF-a, binding to the EGF-R, a 170-kD protein-EGF Or TGF-p, and tyrosine kinase inhibitors. Cell proliferation TGF-a binding to the membrane-bound EGF-R, the reexamined using ~H -T~R incorporation with cell ceptor dimerizes and a tyrosine kinase is activated, lead-counting to corroborate results. ~h~ tyrosine kinase ining to auto~hos~hor~lation the (l2-l6)-This hibitors used were genistein and tyrphostin. Genistein preferentially inhibits ATP binding to a tyrosine kinase 482 CHESS ET AL.
METHODS
Adult male New Zealand White rabbits were euthanized with approximately 70 mglkg pentobarbital. Newborn rabbits were used for inhibitor concentration curve studies, with results confirmed in adults. Animals were approved for use and handled as instructed by the University Committee on Animal Resources. The lungs were removed, and type I1 cells were isolated and cultured on collagen-coated 12-well plates at 2 x lo6 cells per well using the technique previously described by Finkelstein and Shapiro (27) . Using tannic acid staining (28) , it has been routine in our laboratory to obtain 92% cell purity of type I1 cells in culture 22 h after plating (20) .
Tlymidine incorporation studies. Preliminary studies were performed in A549 cells (a human adenocarcinoma cell line) to estimate the range of concentrations of tyrosine kinase inhibitors needed for type I1 cell concentration curves. After 22 h in culture in DMEF12 (Sigma Chemical Co., St. Louis, MO) with 10% FCS, incubating at standard conditions of 37°C and 5% CO,, type I1 cells were exposed to serum-free DMElF12 and incubated for 2 h. Cells were then pretreated with the tyrosine kinase inhibitors genistein at 0.1-20 pM or tyrphostin at 7.5-30 pM, (GIBCO BRL, Grand Island, NY) in serum-free DMEF12 with 5 pCi/mL 3~-T d~ (Amersham, Arlington Heights, IL) for 24 h. Assays for lactate dehydrogenase (Sigma Chemical Co.) were performed in triplicate on cells exposed to 10 p,M genistein or 30 pM tyrphostin, the concentrations used for later experiments, to confirm cell viability. Cells were rinsed with PBS four times, 5% trichloroacetic acid two times, and PBS two times. Cells were collected with three 500-pL aliquots of 0.1 M NaOH and added to 10 mL of scintillation fluid (National Diagnostic, Manville, NJ), and 100 p L of 10% acetic acid were added to neutralize the samples. Samples were allowed to equilibrate overnight before counting with a Beckrnan LS 7500 scintillation counter. After incubating for 22 h in DMEF12 with 10% FCS, cells were incubated in serum-free DMEfF12 for 2 h. Cells were then pretreated with genistein (10 pM) or tyrphostin (30 pM) in serum-free DMElF12 for 2 h. Medium was then changed to include inhibitors with or without TGF-cr (10 nglmL) or TGF-f3 (10 ng/mL) (Collaborative, Bedford, MA) in DMEF12 with 5 pCilmL 3~-T d~ and incubated for 24 h. Samples were collected and counted as previously described. Cell counting was performed in triplicate for several experiments. Cells were counted while plated using a gridded eyepiece (29) .
Western bld analysis. Type I1 cells were isolated and cultured as previously described. Twenty-two hours after plating, cells were placed in serum-free DMEF12 and incubated for 2 h. Cells were pretreated with genistein (10 pM) or tyrphostin (30 pM) for 30 min to 2 h, then exposed to TGF-a (10 ng/mL), TGF-P (10 ng/mL), or both for 30 s to 30 min. Samples were collected in 200-pL Laemmli sample buffer plus 100 pM Na vanadate (Fisher Scientific Co., Fair Lawn, NJ) and 30 mM Na pyrophosphate (Sigma Chemical Co.) to inhibit dephosphorylation (30) , and samples were boiled for 5 min. Protein quantification was performed using bicinchoninic acid analysis (Pierce Chemical Co., Rockford, IL). Approximately 200 pg of protein were loaded per well on an SDS (ICN, Cleveland, OH) polyacrylamide (National Diagnostics, Manville, NJ) gel. The positive control used was phosphorylated EGF-R from A431 cells (UBI, Lake Placid, NY). The molecular weight markers were Rainbow (Amersham, Arlington Heights, IL). Electrophoresis was performed over 3 to 4 h at 35 rnA per gel using a Hoefer apparatus (Hoefer, San Francisco, CA). Proteins were transferred to nitrocellulose (Schleicher and Schuell, Keene, NH) at 2.5 m~/ c m~ for 40 min using an ISS Multiblotter (Enprotech, Natick, MA) dry blotter. Protein transfer was verified using 0.2% Ponceau S (Sigma Chemical Co.) staining, which was removed using 0.1 M NaOH. Nonspecific binding sites were blocked using a blocking solution composed of 5% casein in TBS with 1 mL of Tween 20 and 10 p L of Antifoam A (Sigma Chemical Co.) per liter for 112 h at room temperature. The blots were then incubated overnight at 4°C in 10 mL of 1 pg/mL monoclonal mouse antiphosphotyrosine antibody (UBI) (31) . Blots were washed with blocking solution for 2 x 5 min, then 1 x 15 min, and then incubated for 1 h at room temperature in 10 mL of 1 pg/mL biotinylated goat antimouse IgG (Cappel, Durham, NC). The blots were washed in blocking solution as before, then washed in TBS 2 x 5 min. The blots were then incubated at room temperature for 40 min with Vectastain horseradish peroxidase (Vector, Burlingame, CA) in TBS, then washed with blocking solution and TBS as before. The blots were incubated in enhanced chemiluminescence (Amersham) for 1 min and then exposed to x-ray film (Kodak x-omatar, Rochester, NY) for 3 4 5 min. A Western blot was performed similarly on 200 pg of rabbit type I1 cell protein as previously described using 10 mL of 1 pglmL sheep anti-human EGF-R (UBI) as the primary antibody and 10 mL of 1 pg/mL biotinylated rabbit anti-sheep IgG (Chemicon, Temecula, CA) as the secondary antibody. A Western blot without the primary antibody was performed to identify nonspecific binding.
Data analysis. Analysis of variance with NewmanKeul's post-hoc test was used to compare 3~-~d~ incorporation of control samples with that of growth factorand tyrosine kinase inhibitor-treated samples. A p value of ~0 . 0 5 was considered statistically significant.
RESULTS
Treatment of type I1 cells with genistein at a range of 0.1-20 pM established that incubation with < 1 pM genistein resulted in no inhibition of 3~-~d~ incorporation. Maximal effect was achieved at 10 pM, with approximately 60% inhibition of 3~-~d~ incorporation compared with control (Fig. 1A) . Treatment with tyrphostin at a range of 3-30 pM established that treatment with <10 pM tyrphostin resulted in no inhibition of 3~-~d~ incorporation, and treatment with 30 pM resulted in optimal inhibition, approximately 60% inhibition compared with control (Fig. 1B) . Assays for lactate dehydrogenase confirmed no change in cell viability at 10 pM genistein and 30 pM tyrphostin (data not shown).
Exposure of type I1 cells to genistein (10 pM) or tyrphostin (30 pM) resulted in significant inhibition of basal 3~-~d~ incorporation ( p < 0.05) (Fig. 2) , as well as blocking of the increased 3~-~d~ incorporation seen in response to TGF-a ( p < 0.05) (Fig. 3) . Cell counting confirmed 3~-~d~ incorporation results, with 60-70% inhibition of both 3~-~d~ incorporation and cell number (insets, Figs. 2 and 3 ). To examine further the effects of TGF-a on type I1 cell proliferation, tyrosine phosphorylation was studied. An antiphosphotyrosine antibody was used to examine the response of type I1 cells to growth factors. As expected, addition of TGF-a resulted in phosphorylation of a 170-kD protein corresponding to the known size of the EGF-R by 30 s, peaking by 5 min, and returning nearly to baseline by 30 min (Fig. 4) . Also as expected, the tyrosine kinase inhibitors genistein or tyrphostin inhibited phosphorylation of the presumed EGF-R previously seen in response to TGF-a (Fig. 5) . The inhibition by genistein did not appear to be altered by timing of treatment. The inhibition by tyrphostin was more pronounced when cells were pretreated with tyrphostin for 30 min before addition TGF-a compared with addition of tyrphostin and TGF-a simultaneously. An anti EGF-R antibody confirmed the presence of the EGF-R at 170 kD (Fig. 6) . Exposure of type I1 cells to TGF-P resulted in no newly tyrosine-phosphorylated proteins within 30 min (Fig. 7) . Pretreatment with TGF-P for 30 min resulted in decreased phosphorylation of the presumed EGF-R previously seen in response to TGF-a (Fig. 8) .
DISCUSSION
Previous work has established the importance of protein kinases in regulating cellular functions in type I1 cells. Protein kinase C and CAMP-dependent protein kinase are important in the regulation of surfactant secretion (32) (33) (34) . CAMP-dependent protein kinase activity has been found to be altered at various states of development in the rat lung, possibly to mediate developmental changes in pulmonary response to hormonal stimuli (35) . Actin, a cytoskeletal protein involved in regulating type I1 cell shape and mobility, is phosphorylated via a CAMPdependent protein kinase (36) . Tyrosine kinase activity in type I1 cells in response to TGF-a and TGF-P has not yet been studied.
The results of the current work suggest that tyrosine kinases are important in basal type I1 cell proliferation in vitro a s measured by 3~-~d~ incorporation and cell counting, inasmuch as known tyrosine kinase inhibitors were capable of reducing basal proliferation. In the rat type I1 cell in vitro, TdR incorporation has not always been associated with a concomitant increase in cell number (37) . However, in rabbit type I1 cell proliferation studies, cell number correlated with 3~-~d~ incorporation (20) . In addition to species differences, other factors such as cell density and matrix components may also Figure 4 . TGF-a resulted in rapid phosphorylation of a 170-kD tyrosine protein presumed to be the EGF-R. Rabbit type 11 cells were isolated and plated for 24 h, then treated with 10 ng/mL TGF-a for 30 s to 30 min. Cells were collected in Laemmli sample buffer and subjected to SDS-PAGE using a 12% gel followed by Western blot analysis with an antiphosphotyrosine antibody. Molecular masses are indicated on the left in daltons. G and 47' ). Cells were collected in Laemmli sample buffer and subjected to SDS-PAGE using a 3-17% gradient gel followed by Western blot analysis with an antiphosphotyrosine antibody. Molecular masses are indicated on the left in daltons.
play a role in the relationship between 3~-~d~ incorporation and cell number.
One factor to consider in analyzing and interpreting the data using tyrosine kinase inhibitors is that tyrosine kinases are ubiquitous within living cells. By using tyrosine kinase inhibitors, we may be affecting other vital cellular functions (38) . These effects may be somewhat mitigated by using tyrphostin, a more specific antagonist of the 200,000 -b EGF-R a- Figure 6 . The EGF-R was identified in isolated rabbit type I1 cells at 170 kD. Type I1 cells were isolated and plated for 24 h. Cells were collected in Laemmli sample buffer and subjected to SDS-PAGE using EGF-R tyrosine kinase, and by minimizing exposure times (25, 26 ). It appears that in our system the cellular function affected is specific, inasmuch as tyrphostin and genistein, with different mechanisms of action, achieve similar effects.
Phosphorylation of the EGF-R is a crucial step in the signal transduction pathway initiated by TGF-a in type I1 cells. This event peaks by 30 s to 5 min, a time course comparable to EGF studies in other cell systems (17, 18) . Pretreatment with tyrphostin resulted in more inhibition of EGF-R phosphorylation than simultaneous addition with TGF-a, whereas timing of genistein had little effect. This may be due to tyrphostin being a more specific tyrosine kinase inhibitor or to the cells not being synchronous in their cell cycles.
We have demonstrated that TGF-P decreases the level of phosphorylation of the EGF-R in response to TGF-a. One possible explanation is that TGF-P affects TGF-a binding to its receptor. In previous studies in our laboratory, TGF-P had no effect on EGF binding to the EGF-R for up to 20 min (39) . This is similar to the time course of the EGF-R phosphorylation we studied. Alternatively, TGF-P may enhance dephosphorylation of the EGF-R in response to TGF-a. Fontenay et al. (22) have demonstrated a similar effect of TGF-P decreasing the PDGFinduced phosphorylation of the PDGF receptor, another tyrosine kinase receptor. In their work using human passaged fibroblasts, it appears that TGF-(3 exerts its inhibitory effects on PDGF via serinelthreonine phosphatase activity, resulting in accelerated dephosphorylation of the PDGF receptor. Kim et al. (23) have demonstrated that okadaic acid, a protein phosphatase inhibitor, blocks the proliferative effect of TGF-P on mouse fibroblasts, even when added 10 h after TGF-P treatment. This again supports the involvement of a protein phosphatase beyond the initial activation of the TGF-P-receptor complex in the TGF-P signal cascade.
In conclusion, we have demonstrated that tyrosine kinase activity is important in type I1 pneumocyte proliferation in vitro. TGF-a, known to stimulate type I1 cell proliferation, exerts its effects via phosphorylation of a 170-kD protein, presumed to be the EGF-R. In examining the mechanism by which TGF-f3 blocks the TGF-a mitogenic effect on type I1 cells, we have demonstrated that TGF-P decreases the normal TGF-a-induced phosphorylation of the EGF-R. Additional studies are needed to determine the specific mechanism by which TGF-P affects EGF-R phosphorylation. with Laemmli sample buffer and subjected to SDS-PAGE using a 10% gel followed by Western blot analysis with an antiphosphotyrosine antibody. Molecular masses are indicated on the left in daltons.
